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In vivo investigation of 
hyperpolarized [1,3-13C2]
acetoacetate as a metabolic probe 
in normal brain and in glioma
Chloé Najac1, Marina Radoul1, Lydia M. Le Page1,2, Georgios Batsios1, Elavarasan subramani1, 
pavithra Viswanath1, Anne Marie Gillespie1 & Sabrina M. Ronen1
Dysregulation in NAD+/NADH levels is associated with increased cell division and elevated levels of 
reactive oxygen species in rapidly proliferating cancer cells. Conversion of the ketone body acetoacetate 
(AcAc) to β-hydroxybutyrate (β-HB) by the mitochondrial enzyme β-hydroxybutyrate dehydrogenase 
(BDH) depends upon NADH availability. The β-HB-to-AcAc ratio is therefore expected to reflect 
mitochondrial redox. Previous studies reported the potential of hyperpolarized 13C-AcAc to monitor 
mitochondrial redox in cells, perfused organs and in vivo. However, the ability of hyperpolarized 
13C-AcAc to cross the blood brain barrier (BBB) and its potential to monitor brain metabolism remained 
unknown. Our goal was to assess the value of hyperpolarized [1,3-13C2]AcAc in healthy and tumor-
bearing mice in vivo. Following hyperpolarized [1,3-13C2]AcAc injection, production of [1,3-13C2]β-HB 
was detected in normal and tumor-bearing mice. Significantly higher levels of [1-13C]AcAc and lower 
[1-13C]β-HB-to-[1-13C]AcAc ratios were observed in tumor-bearing mice. These results were consistent 
with decreased BDH activity in tumors and associated with increased total cellular NAD+/NADH. Our 
study confirmed that AcAc crosses the BBB and can be used for monitoring metabolism in the brain. 
It highlights the potential of AcAc for future clinical translation and its potential utility for monitoring 
metabolic changes associated with glioma, and other neurological disorders.
Glioma are the most common type of brain tumors, accounting for up to 30% of all brain tumors and 80% of all 
malignant tumors1. They are categorized into three types (astrocytoma, oligodendroglioma and glioblastoma) 
and four World Health Organization grades (I to IV) based on clinical criteria as well as histological and molecu-
lar features1–4. Of all glioma, glioblastoma (GBM, Grade IV or high-grade) are the most frequent, aggressive and 
lethal brain tumors, with a median survival rate as low as 15 months1. Grade II and III glioma, also referred to 
as low-grade glioma (LGG), have a significantly better prognosis than GBM but survival still remains less than 7 
years2,5. Current standard of care for all brain tumors is a combination of treatments and includes surgical resec-
tion, radiation therapy and chemotherapy4. However, currently, no treatment can fully cure glioma. Therefore, 
new therapies and clinically translatable methods to detect tumors and monitor response, are urgently needed to 
improve patient survival and quality of life.
Independent of their grade, glioma are associated with a broad rewiring of the metabolic pathways allowing 
the tumor to survive and grow6–8. In particular, reactive oxygen species (ROS) are intracellular chemical spe-
cies and byproducts of oxygen metabolism that regulate cell signaling and homeostasis. Elevated ROS levels 
play an important role in tumor development and are associated with increased rates of cell division6,8,9. The 
increase in ROS in cancer cells activates signaling pathways and transcription factors promoting tumorigenesis. 
Subsequently, cancer cells increase their level of antioxidants to prevent cell death and thus allow cancer pro-
gression6,8,9. NADPH plays a major role in controlling cellular redox, regulating glutathione reduction and the 
thioredoxin system10. In LGG, NADPH also plays an important role in tumor development11–14. Specifically, up 
to 70% of LGG and 90% of secondary upgraded GBM harbor a heterozygous missense mutation in one copy of 
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the gene encoding for the isocitrate dehydrogenase 1 (IDH1) enzyme, and this mutation is now recognized as an 
essential driver of LGG development11–13. Mutant IDH1 catalyzes the conversion of α-ketoglutarate (α-KG) to 
2-hydroxyglutarate (2-HG) and NADPH serves as a co-factor for this reaction leading to changes in redox. The 
mutation results in decreased NADPH and glutathione levels and therefore increased ROS levels15. Importantly, 
NADH and NAD+ also play a critical role in controlling cellular redox through several pathways, with some 
studies reporting a direct antioxidant role of NADH and the NAD+-mediated inhibition of ROS10. Furthermore, 
NAD+ kinase allows conversion of NAD+ to NADP+ and nicotinamide nucleotide transhydrogenase transfers 
reducing equivalents from NADH to NADPH. Therefore, the maintenance of both NAD+/NADH and NADP+/
NADPH levels is highly interconnected10. Considering the importance of redox in cancer in general, and in the 
development of LGG in particular, imaging methods that could shed light on redox and associated metabolic 
reactions could help in the non-invasive characterization of glioma.
Several optical methods, using fluorescence or multi-photon microscopy, have been used to measure redox 
in vivo16,17. 31P magnetic resonance spectroscopy (MRS) was also recently used to measure the intracellular 
NAD+/NADH ratio in the healthy human brain and age-dependent changes18,19. A promising approach is the 
use of 13C MRS combined with hyperpolarized metabolites that are metabolized in a redox-dependent manner. 
Indeed, as recently reviewed by us and others, dissolution dynamic nuclear polarization (DNP) leads to a more 
than 10,000-fold enhancement in the signal to noise ratio (SNR) of metabolites and provides a tool to moni-
tor metabolism in real time20,21. Over the past decade, several hyperpolarized 13C agents have been developed 
and applied to the imaging of normal and diseased tissues21. The most common probe, hyperpolarized [1-13C]
pyruvate, is currently in clinical trials for patients with prostate cancer, brain tumors, liver metastases and heart 
disease22,23. To assess cellular redox, previous studies have shown the utility of the hyperpolarized dehydroascor-
bate (DHA)/Vitamin C redox pair in healthy liver, kidney, brain and cancer mouse models24,25. However, the 
toxicity of DHA is likely to limit its clinical translation25. Another redox probe recently reported is hyperpolar-
ized 13C-acetoacetate (13C-AcAc), which was used to assess mitochondrial redox in lymphoma cells, perfused rat 
hearts under ischemia, rat hearts in vivo in fed and fasted conditions, and rat kidneys in vivo26–30. This approach 
is based on the fact that the reversible interconversion of AcAc and β-hydroxybutyrate (β-HB) depends on the 
availability of NADH and the β-hydroxybutyrate dehydrogenase enzyme (BDH), which is located on the inner 
mitochondrial membrane. As such, monitoring the fate of AcAc can serve to assess redox, and previous studies 
indicate that the ratio of acetoacetate-to-β-hydroxybutyrate (AcAc-to-β-HB) is associated with mitochondrial 
redox status (NAD+/NADH)31,32. Importantly for brain studies, AcAc and β-HB are two ketone bodies that serve 
as the brain’s major alternative fuel to glucose, and are transported through the blood brain barrier (BBB), cell 
and mitochondrial membranes via the monocarboxylate transporters (MCT1 and 2)32,33. In addition, previous 
studies show that BDH expression is lower in glioma compared to normal brain, pointing to the potential utility 
of monitoring the fate of hyperpolarized AcAc34,35. Finally, previous work demonstrated that 13C-AcAc fulfills the 
technical requirements for a useful hyperpolarized probe: its polarization enhancement, which represents the 
efficiency of the dissolution DNP method, and the longitudinal T1 relaxation, that characterizes the lifetime of 
the hyperpolarized signal, are both sufficient to monitor metabolism27,28,30. However, to date, we have found no 
reports of the use of hyperpolarized 13C-AcAc in the brain.
The goal of our study was therefore to evaluate the feasibility of using hyperpolarized 13C-AcAc in vivo in 
the brain. We first confirmed that production of hyperpolarized 13C-β-HB can be detected in the healthy mouse 
brain following intravenous injection of hyperpolarized 13C-AcAc. Then, we show that the ratio of hyperpolarized 
13C-β-HB-to-AcAc is lower in tumor-bearing mice when compared to normal controls and that this metabolic 
difference is associated with an increase in total cellular NAD+/NADH (mitochondrial plus cytosolic) ratio and a 
decrease in BDH activity in tumors compared to normal brain tissue.
Results
Characterization of hyperpolarized [1,3-13C2]acetoacetate. [1,3-13C2]acetoacetate ([1,3-13C2]
AcAc) was synthesized by hydrolyzing its ethyl ester with sodium hydroxide (Fig. 1A). It was then dissolved 
in 1:3 water:dimethylsulfoxide with trityl radical OX063 (Oxford Instruments, UK) and gadolinium. Following 
polarization, resonances of [1-13C]AcAc and [3-13C]AcAc were detected with an enhancement of 18 ± 5% (n = 3) 
and 22 ± 4% (n = 3), respectively, when compared to the thermal spectrum (Fig. 1B and Table S1). T1 values of 
hyperpolarized [1-13C]AcAc and [3-13C]AcAc were measured in solution at 11.7T by acquiring dynamic data 
with a short TR and a small flip angle and fitting the decay of hyperpolarized signal using a mono-exponential 
curve (Fig. 1C). Similar to previous reports28,36, the T1 values of hyperpolarized [1-13C]AcAc and [3-13C]AcAc 
were 31 ± 3 sec (n = 5) and 27 ± 1 sec (n = 5), respectively (Table S1). Additional resonances, attributed to [1-13C]
acetone (δ[1-13C]acetone = 216.1 ppm), [1-13C]acetate (δ[1-13C]acetate = 182.1 ppm), unknown contaminants 
(δ[13C]unknown = 180.5, 179.7 and 179.2 ppm) and [13C]bicarbonate (δ[13C]bicarbonate = 161 ppm) were detect-
able on thermal and hyperpolarized data (Fig. 1B,C). Importantly, however, the contaminants do not resonate 
at the frequency of expected metabolic products of interest, i.e. [1-13C]β-HB (δ[1-13C]β-HB = 181.1 ppm) and 
[3-13C]β-HB (δ[3-13C]β-HB = 66.5 ppm).
In vivo hyperpolarized [1,3-13C2]acetoacetate in the healthy and tumor-bearing mouse brain at 
14.1T. Hyperpolarized acquisitions were performed on tumor-bearing animals (U87wt and U87mut mice) 
when tumors reached a volume of ~0.24 cm3 (Fig. 2). Signals from hyperpolarized [1-13C]AcAc, [3-13C]AcAc 
and [1-13C]β-HB could be detected in tumor-bearing and tumor-free animals in hyperpolarized 13C dynamic 
and 90° acquisitions (Fig. 3B,C). However, signal from [3-13C]β-HB could not be detected in all groups due to its 
shorter T1 value. As illustrated in Fig. 3D, summed dynamic data showed a significantly higher SNR for [1-13C]
AcAc in U87wt-bearing mice (n = 8) compared to controls (n = 11) and U87mut-bearing mice (n = 10), but 
no significant differences in the SNR of [1-13C]-β-HB between any of the groups (p value  > 0.35). The ratio of 
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Figure 1. Characterization of the hyperpolarized probe, [1,3-13C2]acetoacetate ([1,3-13C2]AcAc). (A) 
[1,3-13C2]AcAc was prepared by mixing 250 μL of [1,3-13C2]ethyl-AcAc with 4 mL of 1 M NaOH at 37 °C 
for 24 hours. (B) [1,3-13C2]AcAc thermal equilibrium spectrum (1, NT = 16, x80) and first hyperpolarized 
spectrum (2, NT = 1) were acquired at 11.7T and showed a ~20% increase in liquid-state polarization level by 
the dissolution dynamic nuclear polarization technique (NT = number of transient). Resonances of [1-13C]
AcAc (δ[1-13C]AcAc = 175.5 ppm), [3-13C]AcAc (δ[3-13C]AcAc = 210.9 ppm) and 13C-contaminants (δ[1-13C]
Acetate = 182.1 ppm, δ[13C]Unknown = 180.5 ppm and δ[13C]Bicarbonate = 161 ppm) were detectable. (C) 
Stack plot of 13C MR spectra of hyperpolarized [1,3-13C2]AcAc in solution acquired at 11.7T showing decay 
of the hyperpolarized signals as a function of time (temporal resolution 3 sec). Resonances of [1-13C]AcAc 
(δ[1-13C]AcAc = 175.5 ppm), [3-13C]AcAc (δ[3-13C]AcAc = 210.9 ppm) and 13C-contaminants (δ[1-13C]
Acetate = 182.1 ppm, δ[13C]Unknown = 180.5, 179.7, 179.2 ppm and δ[1-13C]Acetone = 216.1 ppm) were 
detectable.
Figure 2. Tumor size quantification. (A) Representative T2-weighted images acquired on a 14.1T MRI scanner 
of U87wt (left) and U87mut (right) tumor-bearing mice and (B) corresponding tumor size quantification at 
time of the hyperpolarized experiments.
4Scientific RepoRts |          (2019) 9:3402  | https://doi.org/10.1038/s41598-019-39677-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
[1-13C]β-HB-to-[1-13C]AcAc was significantly lower in U87wt- and U87mut-bearing mice compared to controls. 
Similar to dynamic data, results from 90° acquisitions also showed a significantly higher SNR for [1-13C]AcAc 
and lower ratio of [1-13C]β-HB-to-[1-13C]AcAc in U87wt- (n = 8) and U87mut-bearing (n = 10) mice compared 
to controls (n = 11) but no differences in the SNR of [1-13C]-β-HB between all groups (p value > 0.46, Fig. 4A,B). 
Quantification of signal from [3-13C]-AcAc showed similar results as signal from [1-13C]AcAc (Fig. S2).
Evaluation of NAD+/NADH ratio and BDH activity in tissues. The enzymatic conversion of ace-
toacetate to β-hydroxybutyrate requires NADH as a co-factor and relies on BDH enzyme activity. To assess if 
changes in the in vivo ratio of [1-13C]β-HB-to-[1-13C]AcAc could be linked to alterations in cellular redox, we 
used a commercial spectrophotometric assay to evaluate the levels of NAD+ and NADH. The hyperpolarized 13C 
slab from which data were acquired contained both tumor and normal-appearing brain tissue for tumor-bearing 
mice, but only normal brain tissue for tumor-free mice. Therefore, tumor and normal-appearing brain tissues 
were collected and freeze-clamped for tumor-bearing mice, while only normal brain samples were collected for 
Figure 3. Representative hyperpolarized 13C data from 1D slab dynamic acquisitions acquired on a 14.1T 
MRI scanner. (A) [1,3-13C2]AcAc metabolism, showing conversion into [1,3-13C2]β-HB mediated by the 
β-hydroxybutyrate dehydrogenase (BDH) enzyme with NADH as a co-factor. (B) Stack plot of hyperpolarized 
13C data acquired from a 1D 10 mm-thick slab (FA = 20°) covering the whole brain of a control mouse 
(tumor-free), showing decay of hyperpolarized [3-13C]AcAc (δ[3-13C]AcAc = 210.9 ppm) and [1-13C]AcAc 
(δ[1-13C]AcAc = 175.5 ppm) and production of hyperpolarized [1-13C]β-HB (δ[1-13C]β-HB = 181.1 ppm) as 
a function of time (time resolution 4 sec). Hyperpolarized acquisitions were started 10 sec after the beginning 
of the hyperpolarized injection (350 μL of [1,3-13C2]AcAc injected over 12 sec). All dynamic data were 
summed. Resonances of [1-13C]AcAc and [1-13C]β-HB were fitted with a Lorentzian-Gaussian line shape 
using MestreNova for each animal and integrals of the fits normalized to SD of the noise were quantified. (C) 
Representative hyperpolarized 13C data obtained from the sum of all dynamic data from a control mouse (left), 
U87wt-bearing mouse (middle) and U87mut-bearing mouse (right), showing that hyperpolarized [1-13C]β-HB 
production could be detected in all three groups. (D) Quantification of [1-13C]AcAc and [1-13C]β-HB levels and 
ratio of [1-13C]β-HB-to-[1-13C]AcAc. A significant increase in [1-13C]AcAc level in U87wt tumor-bearing mice 
and control mice and between U87wt and U87mut tumor-bearing mice was observed. A significant decrease in 
[1-13C]β-HB-to-[1-13C]AcAc ratio in both tumor models compared to normal mice was detected. No difference 
between U87wt and U87mut tumor-bearing mice was observed. SNR, signal to noise ratio; A.U., arbitrary units; 
AcAc, acetoacetate; β-HB, β-hydroxybutyrate.
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tumor-free mice (Fig. 5A). The NAD+/NADH ratios in U87wt tumor samples (n = 7), U87mut (n = 10) tumor 
samples, normal-appearing brain tissue from both tumor groups, and tissue from control tumor-free mice (n = 8) 
were, respectively, 7.8 ± 2.8, 5.1 ± 3.1, 2.9 ± 1.2, 2.3 ± 1.3 and 2.1 ± 0.6 (Fig. 5B). The NAD+/NADH ratio was 
therefore significantly higher in the tumor tissue compared to normal-appearing brain tissue in both U87wt- 
and U87-mut bearing mice as well as compared to normal brain tissue from control mice. We then investigated 
BDH enzyme activity in order to determine if changes in redox and conversion of hyperpolarized [1-13C]AcAc 
to [1-13C]β-HB in our tumor models could also be explained by alterations in the BDH enzyme. BDH enzyme 
activities in U87wt tumor samples (n = 7), U87mut (n = 8) tumor samples, normal-appearing brain tissue sam-
ples and tissue from controls (n = 7) were 0.05 ± 0.03, 0.37 ± 0.30, 0.04 ± 0.03, 0.27 ± 0.16 and 0.36 ± 0.15 μmol/
min/μg of protein respectively (Fig. 5C), thus BDH enzyme activity was significantly lower in tumors compared 
to normal-appearing brain of U87wt- and U87-mut bearing mice as well as compared to normal brain tissue of 
control animals with no tumors.
Discussion
Our goal was to assess the value of hyperpolarized acetoacetate as a probe to monitor redox in the brain and to 
develop a non-invasive MR-based method to image metabolic alterations associated with brain disorders. We 
illustrate here the feasibility of using [1,3-13C2]AcAc and monitoring its conversion to [1,3-13C2]β-HB in healthy 
and tumor-bearing mouse brain in vivo. Our findings are associated with changes in BDH activity as well as alter-
ations in overall cellular NAD+/NADH.
AcAc and β-HB are two ketone bodies that can serve as the brain’s main alternative fuels to glucose. They are 
rapidly transported via monocarboxylate transporters through the BBB into cells and mitochondria32,33. As such, 
we could readily detect the delivery of hyperpolarized AcAc into the brain of a normal mouse. Furthermore, no 
toxic effects were observed in our study following intravenous injection of AcAc, consistent with previous stud-
ies26–28,30. Beyond its biological utility, our study confirmed previous reports that [1,3-13C2]AcAc fulfills the tech-
nical requirements for dissolution DNP and is therefore a promising hyperpolarized probe26–28. Specifically, the 
liquid-state polarization levels (~20%) were sufficient to achieve adequate SNR for monitoring the fate of AcAc, 
and both labeled carbons (C1 and C3) have T1 relaxation times that are long enough for detection of metabolism 
(~30 sec). Our study was performed at relatively high magnetic fields (11.7 and 14T), and longer T1 values are 
expected at lower clinical magnetic fields for labeled carboxyl groups, as previously illustrated by a study at 3T30. 
Labeling of AcAc on C1 and C3 allows for potential detection of signal from C1 and C3 of β-HB following met-
abolic conversion by BDH enzyme. Importantly, there is sufficient chemical shift separation between substrate 
and product, i.e. 5.6 ppm between [1-13C]AcAc and [1-13C]β-HB and 144.6 ppm between [3-13C]AcAc and [3-13C]
β-HB26,30. A recent study also reported a T1 value for [1-13C]β-HB of ~20 sec at 11.7T28, which is sufficiently 
long to detect signal in vivo. But it should be noted that in the case of [3-13C]β-HB, the directly bonded proton 
leads to a very short T1 that precluded detection of this second signal in vivo in our study at high field. A poten-
tial limitation of AcAc is that it is not commercially available because of its natural instability and spontaneous 
Figure 4. Representative hyperpolarized 13C data from 1D slab 90° acquisitions acquired on a 14.1T MRI 
scanner. (A) Representative hyperpolarized 13C data acquired from a 1D 10 mm-thick slab (FA = 90°) in a 
control mouse (top), U87wt-bearing mouse (middle) and U87mut-bearing mouse (bottom). Signals from 
hyperpolarized [3-13C]AcAc (δ[3-13C]AcAc = 210.9 ppm), [1-13C]AcAc (δ[1-13C]AcAc = 175.5 ppm) and [1-13C]
β-HB (δ[1-13C]β-HB = 181.1 ppm) could be detected in all three groups. Resonances of [1-13C]AcAc and [1-13C]
β-HB were fitted with a Lorentzian-Gaussian line shape using MestreNova for each animal and integrals of the 
fits normalized to SD of the noise were quantified. (B) Quantification of [1-13C]AcAc and [1-13C]β-HB levels 
and ratio of [1-13C]β-HB-to-[1-13C]AcAc showed a significant increase in [1-13C]AcAc level and a significant 
decrease in [1-13C]β-HB-to-[1-13C]AcAc ratio in both tumor models compared to normal mice. No difference 
between U87wt and U87mut tumor-bearing mice was observed. SNR, signal to noise ratio; A.U., arbitrary units; 
AcAc, acetoacetate; β-HB, β-hydroxybutyrate.
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decarboxylation to acetone and carbon dioxide. Therefore, 13C-AcAc needs to be synthesized prior to each set of 
hyperpolarized experiments.
Recent studies illustrated the potential of using hyperpolarized [1,3-13C2]AcAc as a biomarker of mitochon-
drial redox in vivo in the abdomen and in the heart28,30. Here we showed, to our knowledge for the first time, the 
feasibility of using hyperpolarized [1,3-13C2]AcAc to probe metabolism in the brain. Following intravenous injec-
tion of [1,3-13C2]AcAc, we were able to clearly monitor the production of [1-13C]β-HB in healthy mice demon-
strating the utility of this hyperpolarized agent for brain studies.
As previously mentioned, the IDH1 mutation is the most prevalent driver mutation in low-grade glioma and 
upgraded secondary glioblastoma11,13. It is responsible for the conversion of α-KG to 2-HG using NADPH as a 
cofactor37,38, and previous studies have shown that the mutation results in increased reactive oxygen species, and 
changes in NADPH15,39,40. Nonetheless, and although NADP+/NADPH and NAD+/NADH are interconnected10, 
we did not observe any difference in the NAD+/NADH ratio between the U87 IDH1 wild type and U87 IDH1 
mutant tumor extracts (p value = 0.09). We also did not observe any difference in BDH enzyme activity in these 
tumor tissues (p value = 0.97). A possible reason is that our model was generated by genetically engineering glio-
blastoma cells to express mutant or wild type IDH1. As such, our cells might not fully recapitulate the complete 
metabolic signature associated with IDH1 mutant glioma. Indeed, a previous study in our lab did not find any 
differences in NADP+/NADPH between our two models (Fig. S3). Importantly however, consistent with the 
comparable NAD+/NADH ratios and BDH activities, we also observed that the ratio of hyperpolarized [1-13C]
β-HB-to-[1-13C]AcAc was comparable between mice bearing U87wt tumors and mice bearing U87mut tumors 
(p value = 1).
When comparing tumor-bearing mice to controls, an increase in the hyperpolarized [1,3-13C2]AcAc signal was 
observed in the U87wt-tumor mice in the dynamic acquisitions. Similarly, in the 90° acquisitions, we observed 
an increase in the [1,3-13C2]AcAc signal in the U87wt-bearing mice compared to control mice, and an increase in 
[1-13C]AcAc and a trend towards an increase in [3-13C]AcAc in U87mut-bearing mice (p value = 0.15). The small 
Figure 5. NAD+/NADH ratio and BDH activity quantified by spectrophotometric assays. (A) 1D slab 
13C acquisitions were 10 mm-thick and therefore covered the whole brain. In tumor-bearing mice, the slab 
contained both tumor and normal-appearing brain whereas in tumor-free (control) mice, it contained only 
normal brain. At sacrifice, both normal-appearing and tumor tissues from tumor-bearing mice and normal 
brain tissues from control mice were freeze-clamped and kept at −80 °C for spectrophotometric assays. (B) 
NAD+ and NADH levels were measured and NAD+/NADH ratios were quantified. No differences were 
observed in NAD+/NADH ratio between control normal brain tissue and tumor-bearing mouse normal-
appearing brain tissue and between U87wt and U87mut tumor tissue. A significant increase in NAD+/NADH 
ratio was observed between controls normal brain and U87wt/U87mut tumor tissues as well as between tumor-
bearing normal-appearing brain tissues and U87wt/U87mut tumor tissues. (C) BDH activity from isolated 
mitochondria was quantified. No differences were observed between controls normal brain tissues and tumor-
bearing mice normal-appearing brain tissues. A significant decrease in BDH activity in tumor tissues compared 
to normal-appearing brain tissues was observed for both tumor models. A significant decrease was measured 
between U87wt and U87mut tumor tissues and normal brain tissues from healthy controls. N.B., Normal Brain; 
N-A.B., Normal-Appearing Brain; T., Tumor.
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differences between dynamic and 90° acquisitions are likely due to differences in SNR. The higher [1,3-13C2]AcAc 
in tumor-bearing mice is likely due to an increase in its delivery to the tumor region as a result of breakdown 
of the BBB and increased vascular permeability41–43. However, although [1,3-13C2]AcAc signal was increased in 
tumor-bearing mice, no changes in the [1-13C]β-HB levels were detected, pointing to reduced metabolism in the 
tumor tissue. As a result, there was a significantly lower (~38%, average for U87wt and U87mut tumors) [1-13C]
β-HB-to-[1-13C]AcAc ratio in the brain of tumor-bearing mice compared to tumor-free healthy controls.
To assess the association between lower conversion of [1-13C]AcAc to [1-13C]β-HB and cellular metabolism 
we determined cellular NAD+/NADH and mitochondrial BDH enzyme activity using spectrophotometric assays. 
The cellular NAD+/NADH ratios reported here were within the range of values found in the literature18,44. The 
increase observed in our tumors was consistent with one previous study45 but most previous reports suggest that 
the ratio of NAD+/NADH should decrease in cancer cells46. However, it should be noted that we are comparing 
tumor tissue of human origin to normal tissue from the rodent. Thus the primary value of this data is in assess-
ing the significance of our hyperpolarized information. Our studies showed a significant increase (~60–70%) in 
NAD+/NADH in the tumor tissues compared to normal brain, which is consistent with the hyperpolarized obser-
vations. Nonetheless, as mentioned above, the metabolism of AcAc occurs in the mitochondrial compartment, 
whereas our ex vivo NAD+/NADH measurement represents an average of the mitochondrial and cytosolic pools 
(the kit used does not allow differentiation between the NAD+ and NADH pools (both free and bound forms) of 
the cytosol and mitochondria). Therefore, the increase in NAD+/NADH ratio measured here in tumor-bearing 
mice cannot directly be linked to changes in redox at the level of the mitochondria. Another limitation of our 
study is that, due to insufficient SNR, kinetic analysis of the hyperpolarized data could not be conducted, and 
therefore we cannot ascertain that equilibrium between AcAc and β-HB has been reached. As a result we cannot 
directly infer the mitochondrial NAD+/NADH ratio from our hyperpolarized measurement. In contrast how-
ever, our findings with regard to the activity of the BDH enzyme identify a likely link between hyperpolarized 
AcAc metabolism and enzyme activity that were both significantly reduced in tumor tissues compared to normal 
brain. Lower BDH activity is also consistent with previous reports showing a decrease in BDH activity in a rat 
hepatoma cell lines compared to normal rat hepatocytes47. This finding is also in good agreement with published 
data reporting lower BDH-1 expression in glioma cells compared to normal brain34,35. Collectively, our findings 
therefore support the conclusion that the hyperpolarized [1-13C]β-HB-to-[1-13C]AcAc ratio is informative of 
mitochondrial BDH activity and could be indicative of cellular NAD+/NADH ratio.
Further work is needed to acquire 2D images of [1-13C]β-HB production and distribution. For instance, a 
multiband pulse sequence that applies a small flip angle to 13C-AcAc to preserve its magnetization while a larger 
flip angle is applied to [13C]β-HB to increase its SNR, would improve the likelihood of detecting metabolism at a 
higher spatial resolution and performing kinetic analysis. Nonetheless, the low toxicity of AcAc and its ability to 
cross the BBB are encouraging for translation of this hyperpolarized agent to the clinic. In addition, as mentioned 
above, the lower magnetic field used in the clinic will increase the T1 of both [1-13C]AcAc and [1-13C]β-HB, facil-
itating the detection of metabolism.
Beyond cancer, previous studies have reported changes in the ratio of AcAc-to-β-HB in the immature rat 
brain under cerebral metabolic stress (hypoxia, ischemia, anoxia) and in the aging rat brain48,49. In addition, other 
reports illustrate the importance of BDH in oxidative stress models, and of ketone bodies in parkinson disease 
and traumatic brain injury32,50,51. These investigations point to the potential of AcAc for investigating a range of 
neurological diseases.
In summary, this study shows for the first time the feasibility of using hyperpolarized [1,3-13C2]AcAc to mon-
itor the conversion of AcAc to β-HB in the brain and in glioma in vivo. The reduced β-HB production in tumor 
models in vivo was consistent with lower BDH activity and in agreement with higher NAD+/NADH. Our findings 
thus demonstrate the potential of this hyperpolarized agent to measure metabolism in the normal and diseased 
brain.
Materials and Methods
[1,3-13C2]Acetoacetate synthesis. [1,3-13C2]acetoacetate ([1,3-13C2]AcAc) was synthesized by hydrolyz-
ing its ethyl ester with sodium hydroxide as previously described27,28,52,53. Briefly, 250 μL 1 M [1,3-13C2]ethyl-ace-
toacetate ([1,3-13C2]ethyl-AcAc, Sigma, USA) was mixed with 4 mL 1 M sodium hydroxide (Sigma, USA) at 37 °C 
for 24 hours. The mixture was frozen at −80 °C and lyophilized for 24 hours. The powder was resuspended in 
a mixture of 1:3 water:dimethylsulfoxide. The stock solution was aliquoted and kept at −80 °C. 13C MR spec-
tra of the product mixture were acquired on an 11.7T MR Bruker Avance spectrometer equipped with a triple 
resonance cryoprobe to confirm synthesis of [1,3-13C2]acetoacetate (n = 3). Proton-decoupled 13C spectra were 
acquired using a 30° flip angle, 3 sec repetition time (number of transients (NT) = 96, spectral width (SW) = 30k, 
number of points (np) = 32k). In addition, a fully relaxed spectrum (flip angle (FA) = 90°, TR = 300 sec and 
broad-band decoupling acquired during the acquisition time) was recorded and served to determine correction 
factors for saturation and Nuclear Overhauser effect. A coaxial insert containing 43 mM sodium 3-(trimethyl-
silyl)propionate-2,2,3,3-d4 (TSP) was used as an external reference to verify chemical shift and estimate con-
centration of [1,3-13C2]AcAc (Fig. S1). Prior to Fourier transformation, a line broadening of 1 Hz was applied to 
FIDs. [1-13C]AcAc (δ[1-13C]AcAc = 175.5 ppm), [3-13C]AcAc (δ[3-13C]AcAc = 210.9 ppm) and [13C]TSP (δ[13C]
TSP = −2.2 ppm) signals were quantified by peak integration using MestreNova (Mestrelab, Spain). We calculated 
a final [1,3-13C2]AcAc stock solution concentration of ~2.4 M (Fig. S1).
[1,3-13C2]Acetoacetate hyperpolarization. Prior to each dissolution DNP experiment, 15 mM of trityl 
radical OX063 (Oxford Instruments, UK) and 1 mM of Gadolinium-Dotarem (Macrocyclics, USA) were added 
to the 13C-labeled stock solution. As previously shown, gadolinium increases the amount of polarization that 
can be reached using DNP54. For all experiments, aliquots (~100 mg) were polarized for ~3 hours using either a 
8Scientific RepoRts |          (2019) 9:3402  | https://doi.org/10.1038/s41598-019-39677-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
HyperSense DNP system or Test-bed polarizer (3.35T, 1.4 K, Oxford Instruments) and subsequently rapidly dis-
solved in 4.2 mL of buffer (40 mM Tris-HCl (pH8), 3 μM Ethylenediaminetetraacetic acid (EDTA), 22 μM HCl) to 
yield ~50 mM solutions of hyperpolarized [1,3-13C2]AcAc.
Relaxation and polarization levels. Following beginning of dissolution, 2 mL of hyperpolarized [1,3-
13C2]AcAc was transferred within ~20-25 sec into a 10 mm NMR tube at 37 °C. Dynamic 13C spectra were then 
acquired immediately using a non-localized single pulse acquisition (TR = 3 sec, FA = 5°, SW = 20 kHz, np = 20 k, 
NT = 100, number of repeats (n) = 5) on a 11.7T INOVA spectrometer (Agilent Technologies, USA) using a 
10 mm broadband probe. Following total decay of the hyperpolarized signal, a thermal equilibrium spectrum 
was acquired using FA = 90°, TR = 300 sec, NT = 16 and other parameters identical to the ones mentioned above 
(n = 3). T1 of hyperpolarized [1-13C]AcAc and [3-13C]AcAc were determined by quantifying peak integrals using 
MestreNova, correcting for flip angle, and fitting the signal decay with a mono-exponential curve. The level 
of polarization in solution was calculated by comparing the signal on the first hyperpolarized spectrum of the 
dynamic set to the corresponding signal in the thermal equilibrium spectrum, after correction for flip angle and 
number of transients.
Animal models. All studies were conducted in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of California (San Francisco, CA). A total of 28 6-week old female athymic nu/nu mice 
were used. 8 mice served as tumor-free controls and 20 mice were intracranially injected with 3 × 105 tumor cells. 
8 mice were implanted with IDH1 wild-type (U87wt) U87 cells and 12 with U87 cells genetically-engineered to 
express mutant IDH1 (U87mut)37. 4 U87mut and 1 U87wt mice underwent the hyperpolarized study prior to 
tumor implantation and served as additional tumor-free controls. Prior to implantation, cell lines were main-
tained between passages 15 and 30 in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
calf serum, 2 mM glutamine, and 100 U/ml penicillin and streptomycin under normoxic conditions37. Both cell 
lines were routinely tested for mycoplasma contamination and authenticated by short tandem repeat fingerprint-
ing (Cell Line Genetics) within 6 months of any study.
MRI and hyperpolarized 13C MRS studies in vivo. Studies were performed on a 14.1T vertical MR 
system (Agilent technologies). Animals were anesthetized using isoflurane (1–2% in O2, 1 L/min). Axial ana-
tomical T2-weighted images were acquired using a multi-slice spin-echo sequence (TE = 20 ms, TR = 1200 ms, 
in-plane resolution = 0.12 × 0.12 mm3, slice thickness (thk) = 1 mm, number of acquisition (NA) = 2) and a single 
channel volume 1H coil in order to monitor tumor size. Once tumors reached a volume of ~0.24 cm3, hyperpo-
larized experiments were performed on tumor-bearing animals using a dual-tune volume 1H-13C coil. Prior to 
hyperpolarized studies, a 27-gauge catheter was secured in the tail vein for injection of hyperpolarized material. 
T2-weighted images were acquired using a multi-slice spin-echo sequence (same parameters as above, except 
thk = 1.5 mm) to position a 10 mm-thick axial 13C slab through the brain for hyperpolarized acquisitions. Each 
mouse was injected with 350 μL of hyperpolarized [1,3-13C2]AcAc solution in the tail-vein over 12 sec. Dynamic 
13C slice-localized spectra (FA = 20°, NT = 10) were acquired every 4 sec from the 10 mm-thick slab, starting at 
the end of the injection, followed by a 90° 13C slice-localized acquisition (NT = 1). Tumor-free mice (controls) 
underwent the same hyperpolarized experiments as tumor-bearing mice.
In vivo MR data analysis. Tumor size was measured by manually contouring the tumor area in each slice 
and summing all the areas multiplied by slice thickness using in-house MR software (MRSC Image). Tumor size 
was quantified for each animal. The hyperpolarized experiments were performed when the tumor reached a 
volume of ~0.24 cm3. Hyperpolarized 13C MRS data were analyzed as follows using MestreNova. Each 13C spec-
trum from the dynamic set was apodized (line broadening (lb) = 20 Hz) and phased. All dynamic data were then 
summed. 13C spectra from 90° acquisitions were apodized (lb = 40 Hz) and phased. Resonances of [1-13C]AcAc, 
[3-13C]AcAc and [1-13C]β-HB were fitted with a Lorentzian-Gaussian line shape. Finally, integrals of the fits were 
normalized to standard deviation (SD) of the noise and ratios of [1-13C]β-HB-to-[1-13C]AcAc were quantified for 
each animal.
Spectrophotometric assays. Following hyperpolarized experiments, animals were euthanized and tis-
sue collected for spectrophotometric assays. Hyperpolarized signal was recorded from a 10 mm-thick slab that 
included both tumor and normal brain tissues for tumor-bearing mice, and normal brain only for controls. 
Therefore, both tumor and normal-appearing brain tissues were collected and freeze-clamped for tumor-bearing 
mice, while normal brain tissue was only collected for tumor-free mice. All tissue samples were kept at −80 °C 
until they were processed for the spectrophotometric assays. NAD+ and NADH levels were quantified for each 
sample (~25 mg, n = 7 U87wt samples, n = 10 U87mut samples, n = 8 tumor-free samples) using a commercial 
colorimetric kit (BioVision, USA) and following manufacturer instructions. BDH enzyme activity was quantified 
(~25 mg, n = 7 U87wt samples, n = 8 U87mut samples, n = 7 tumor-free samples) using previously described 
methods55. The collected tissue was first used to conduct the NAD+/NADH assay, therefore for some samples, 
not enough tissue remained for the BDH activity assays resulting in less repeats for the BDH assay. For both 
assays and all samples, tissues were homogenized using a tissue lyser (Qiagen, USA) and further processed as 
follows. NAD+/NADH ratio: Briefly, NADt (NAD++NADH) was extracted following manufacturer instructions. 
For each of the extracted samples, half of the sample was heated to 60 °C for 30 min to decompose NAD+ while 
keeping NADH intact. Both NADt and NADH samples were mixed with NAD cycling enzyme and absorbance 
was measured at 450 nm using an Infinite 300 m200 spectrophotometer (Tecan Systems, Inc., USA). NADt and 
NADH were quantified by comparing with NADH standard curve and normalizing to mg of protein (determined 
by a Bradford protein assay). Finally, ratios of NAD+ (NADt - NADH) to NADH were calculated. BDH enzyme 
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activity: Briefly, mitochondria were isolated using a kit (ThermoFisher Scientific, USA) and were then resus-
pended in buffer (containing 10 mM Tris-HCl, 0.1 mM EDTA, 0.5 mM Dithiothreitol) and mixed with NADH 
(Sigma, USA, final concentration 0.2 mM) and lithium AcAc (Sigma, USA, final concentration 5 mM) or with 
NADH only (blank, final concentration 0.2 mM). NADH consumption was monitored for 30 min by measuring 
absorbance at 450 nm using an Infinite 300 m200 spectrophotometer. The slope of NADH consumption as a 
function of time was measured. Activity of enzyme was calculated by subtracting the slope of the blank (without 
AcAc) from the slope of the corresponding sample (with AcAc), converting absorbance/min into μmol/min using 
NADH standard, and normalizing to mg of mitochondria protein (determined by a Bradford protein assay).
Statistical analyses. Results are expressed as mean ± SD. One-way ANOVA was used to determine statisti-
cal differences in hyperpolarized 13C MRS data between U87-bearing mice and control mice. One-way ANOVA 
was also used to compare NAD+/NADH ratios and BDH enzyme activities between U87wt/U87mut mice tum-
ors, U87wt/U87mut mice normal-appearing and control brain tissues. For hyperpolarized and NAD+/NADH 
data, p values were corrected for multiple testing using the Tukey honest significant difference (HSD) post hoc 
test. An unpaired t-test was used to determine statistical significance of tumor size measured by T2-weighted MRI 
between U87wt and U87mut mice (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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